Loading…
Glaukos Corporation is projected to rise to $185.49 by 2027, a +21% move from its current price of $152.72. GKOS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $149.17 | $152.85 | $156.62 | +0.08% |
| Jul 14 | $147.79 | $152.98 | $158.34 | +0.17% |
| Jul 15 | $146.78 | $153.10 | $159.70 | +0.25% |
| Jul 16 | $145.94 | $153.23 | $160.89 | +0.34% |
| Jul 17 | $145.23 | $153.36 | $161.95 | +0.42% |
| Jul 18 | $144.60 | $153.49 | $162.93 | +0.50% |
| Jul 19 | $144.03 | $153.62 | $163.85 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $144.03 | $153.62 | $163.85 | +0.59% |
| Week 2 | $141.06 | $154.52 | $169.27 | +1.18% |
| Week 3 | $139.01 | $155.43 | $173.79 | +1.78% |
| Week 4 | $137.43 | $156.35 | $177.86 | +2.37% |
| Week 5 | $136.15 | $157.27 | $181.65 | +2.98% |
| Week 6 | $135.08 | $158.19 | $185.25 | +3.58% |
| Week 7 | $134.17 | $159.12 | $188.72 | +4.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc.
Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation (GKOS) is an ophthalmic healthcare company currently priced at $152.96 with a market capitalization of $8.98B and a rank of 983. The stock sits in the healthcare sector, focused on glaucoma and related ocular conditions through its portfolio of implants, injectables, and complementary platforms.
A major floor 44.3% below — a decisive break under it would weaken the trend.
The nearest floor, 32.5% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 23.7% above — clearing it would confirm fresh momentum.
Key GKOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GKOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $152.02 | Buy | $151.43 | Buy |
| MA 10 | $147.24 | Buy | $147.50 | Buy |
| MA 20 | $139.27 | Buy | $141.33 | Buy |
| MA 50 | $132.37 | Buy | $132.74 | Buy |
| MA 100 | $122.91 | Buy | $125.45 | Buy |
| MA 200 | $111.80 | Buy | $117.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.79 | Neutral |
| Stoch RSI (14) | 73.01 | Neutral |
| CCI (20) | 105.88 | Buy |
| Williams %R (14) | -9.84 | Info |
| MACD (12,26,9) | 1.52 | Buy |
| ROC (12) | 13.42 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 90.16 | Sell |
| TRIX (15) | 0.62 | Buy |
| Awesome (5,34) | 21.89 | Buy |
| Ultimate (7,14,28) | 78.62 | Sell |
| Momentum (10) | 10.15 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 156.22 | Sell |
| ADX (14) | 26.49 | Buy |
| ATR (14) | 3.08 | Info |
The 30-day technical picture remains bullish, with RSI(14) at 70 and the stock trading above both the SMA50 ($131.05) and SMA200 ($111.11). These moving averages indicate a constructive near-term trend. Support is cited at $103.12 and resistance at $152.96, with a 30-day price range from $129.27 to $181.00.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $97.02 | $152.72 | $216.88 | 0% | Neutral | |
| $149.15 | $185.49 | $243.12 | +21% | Bullish | |
| $183.59 | $234.00 | $317.15 | +53% | Bullish | |
| $232.99 | $303.08 | $421.72 | +98% | Bullish | |
| $241.25 | $319.50 | $454.52 | +109% | Bullish | |
| $260.95 | $351.25 | $509.49 | +130% | Bullish | |
| $278.23 | $380.22 | $561.20 | +149% | Bullish | |
| $290.99 | $403.32 | $604.77 | +164% | Bullish | |
| $365.77 | $513.83 | $781.77 | +236% | Bullish | |
| $408.79 | $581.66 | $897.03 | +281% | Bullish | |
| $574.57 | $866.22 | $1,414.05 | +467% | Bullish | |
| $1,030.91 | $1,714.65 | $3,042.32 | +10.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $97.02 | $152.72 | $185.14 | +0.00% |
| August 2026 | $138.47 | $162.96 | $196.57 | +6.70% |
| September 2026 | $139.21 | $164.85 | $200.85 | +1.16% |
| October 2026 | $138.91 | $165.38 | $203.20 | +0.32% |
| November 2026 | $142.90 | $170.90 | $211.47 | +3.34% |
| December 2026 | $145.00 | $174.14 | $216.88 | +1.90% |
Click any year to see its month-by-month GKOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GKOS price prediction for 2026 points to an average of $152.72 (low $97.02, high $216.88) — a potential gain of 0% on today's $152.72. A consolidation phase looks the most probable path here.
In 2027, GKOS is projected to trade between $149.15 and $243.12, averaging $185.49 — a potential gain of +21% from today's $152.72. That is up +21% on the projected 2026 average. Momentum favours further upside here.
Glaukos Corporation's 2028 outlook centres on $234.00, within a $183.59 to $317.15 range. That is up +26% on the projected 2027 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, GKOS could reach as high as $421.72, with a base case around $303.08 and support toward $232.99 — roughly +98% from $152.72. Momentum favours further upside here.
Expect GKOS to range from $241.25 to $454.52 through 2030. The $319.50 average target implies a +109% move from current prices. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GKOS price prediction for 2031 points to an average of $351.25 (low $260.95, high $509.49) — a potential gain of +130% on today's $152.72. Momentum favours further upside here.
In 2032, GKOS is projected to trade between $278.23 and $561.20, averaging $380.22 — a potential gain of +149% from today's $152.72. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Glaukos Corporation's 2033 outlook centres on $403.32, within a $290.99 to $604.77 range. That is up +6% on the projected 2032 average. That marks a +164% change versus current levels. Momentum favours further upside here.
By 2034, GKOS could reach as high as $781.77, with a base case around $513.83 and support toward $365.77 — roughly +236% from $152.72. Buyers look set to stay in control over this stretch.
Expect GKOS to range from $408.79 to $897.03 through 2035. The $581.66 average target implies a +281% move from current prices. That is up +13% on the projected 2034 average. Momentum favours further upside here.
The GKOS price prediction for 2040 points to an average of $866.22 (low $574.57, high $1,414.05) — a potential gain of +467% on today's $152.72. Buyers look set to stay in control over this stretch.
In 2050, GKOS is projected to trade between $1,030.91 and $3,042.32, averaging $1,714.65 — a potential gain of +10.2x from today's $152.72. That is up +98% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GKOS today (≈ 6.547931 GKOS) could be worth
$11,227.39
+$10,227.39 (+1023%) by 2050 · US Dollar
Based on the average projected GKOS price of $1,714.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GKOSwould be worth at today's price.
$1,000 invested in GKOS on Jul 10, 2025 (≈ 9.385265 GKOS) would be worth
$1,433.32
+$433.32 (+43.3%) today · 1.43× · US Dollar
Based on a GKOS entry price of $106.55 vs. today's $152.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $148.34 | $1,029.53 | +3.0% |
| 1 month ago | $122.49 | $1,246.8 | +24.7% |
| 3 months ago | $116.4 | $1,312.03 | +31.2% |
| 6 months ago | $110.91 | $1,376.97 | +37.7% |
| 1 year ago | $106.55 | $1,433.32 | +43.3% |
| All time (5.0y) ago | $73.57 | $2,075.85 | +107.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GKOS forecast.
Our base-case forecast reaches $310.00 around 2030.
Implied market cap at $310.00: $18.21B
The multi-year forecast shows a bullish path from 2027 through 2050. The 2027 average price is $185.60 with a 21.3% ROI; by 2028 the average is $236.62 (ROI 54.7%), and by 2030 the average is $322.10 (ROI 110.6%). By 2040 the average price is $882.35 (ROI 476.9%), and by 2050 the average price is $1,730.87 (ROI 1031.6%) with a max forecast of $3,122.17.
The outlook remains bullish across these years, though these are estimates and not guarantees. Investors should consider the potential for variability and volatility alongside the upside potential.
Tap a question to reveal the answer.
2026 min $97.02, avg $152.96, max $218.52; ROI 0; sentiment NEUTRAL.
The forecast shows bullish sentiment from 2027 onward with rising averages and positive ROIs (e.g., 2027 avg $185.60; 2028 $236.62; 2029 $307.04; 2030 $322.10; 2040 $882.35; 2050 $1,730.87), though 2026 is neutral.
Yes. The 2030 forecast lists max $462.36 and an average of $322.10, with a min of $241.41 and ROI 110.6%.
Yes. The 2050 forecast lists max $3,122.17 and average $1,730.87, with a min of $1,018.32 and ROI 1031.6%.
For 2040, the forecast shows min $576.49, avg $882.35, max $1,460.46, ROI 476.9%, sentiment BULLISH.
Glaukos Corporation Community Discussion
0Share your Glaukos Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.